Ebola: Basics About the Disease

Ebola: Basics About the Disease

name redacted

Specialist in Public Health and Epidemiology

October 3, 2014

Congressional Research Service

7-....

www.crs.gov

R43750

Ebola: Basics About the Disease

I

n March 2014, global health officials recognized an outbreak of Ebola virus disease (EVD) in

Guinea, West Africa. In retrospect, officials determined that the outbreak began in December

2013, and spread to the adjacent countries of Liberia and Sierra Leone. In September 2014,

the U.S. Centers for Disease Control and Prevention (CDC) confirmed the first EVD case

diagnosed in the United States,1 heightening concerns among some who fear the disease could

spread in American communities.2 This report discusses EVD in general, including symptoms,

modes of transmission, incubation period, and treatments; presents projections of the future

course of the outbreak; and lists additional CRS products, including products focused on the

situation in West Africa. Unless otherwise cited, information in this report is drawn from Ebola

information pages of CDC3 and the World Health Organization (WHO).4

Figure 1. Ebola Virus Particle

Source: Colorized transmission electron micrograph

from CDC, Public Health Image Library, image

#10815, http://phil.cdc.gov.

The Ebola Virus and EVD

The Ebola virus is named after the Ebola

River, near where the virus was discovered in

1976 in Zaire, now known as the Democratic

Republic of the Congo (DRC). It is in the

filovirus family, so called because of its

filamentous shape. EVD is also known as

Ebola hemorrhagic fever. The disease

sometimes causes hemorrhage (i.e., bleeding)

from body openings, but this symptom is not

consistent. Five strains of Ebola virus have

been identified. The Zaire strain is

responsible for the current outbreak in West

Africa. A slightly different Zaire strain is

responsible for a smaller unrelated outbreak

now in the DRC.

Transmission

Ebola virus is thought to live in nonhuman animals in parts of Africa. Fruit bats are thought to be

the most likely or most common animal reservoir for the virus. Humans may be exposed through

contact with infected animals.

During an outbreak, EVD spreads through human-to-human transmission. Transmission requires

direct contact with body fluids from an infected person or contaminated objects such as medical

equipment. It cannot be spread through the air. Hence, EVD is not as easily transmitted as

influenza or common cold viruses, which can be spread through the air. However, healthcare

workers, family members, and others who care for EVD patients have a high risk of infection

because they are in regular contact with infected body fluids.

1

Centers for Disease Control and Prevention (CDC), “CDC and Texas Health Department Confirm First Ebola Case

Diagnosed in the U.S.,” press release, September 30, 2014,

2

CRS Report IN10126, Safe at Home? Letting Ebola-Stricken Americans Return, by (name redacted).

3

Centers for Disease Control and Prevention (CDC), “Ebola virus disease,” http://www.cdc.gov/vhf/ebola/index.html.

4

World Health Organization (WHO), “Ebola virus disease,” http://www.who.int/csr/disease/ebola/en/.

Congressional Research Service

1

Ebola: Basics About the Disease

In humans EVD has an incubation period—the time between exposure and onset of symptoms—

from 2 to 21 days, with an average of 8 to10 days. Individuals are not contagious, meaning they

cannot transmit EVD to others, until symptoms are present. Those surviving infection may still

have Ebola virus in their bodies and remain contagious for several months after infection, even

when symptoms are no longer present. They can be tested for the presence of virus in order to

maintain their quarantine until they are no longer contagious.

Symptoms and Diagnosis

The early symptoms of EVD are shared by many more common illnesses, complicating

diagnosis.5 Symptoms may include a high fever (greater than 38.6°C, or 101.5°F), severe

headache, muscle pain, weakness, diarrhea, vomiting, abdominal (stomach) pain, and unexplained

hemorrhage (bleeding or bruising).

Several laboratory tests are available to test patients

for EVD. These tests may yield negative results

within the first few days after symptoms appear. As

a result, patients who have potentially been

exposed to EVD and who show some of the

symptoms above should be isolated, even if test

results are negative, and retested a few days later.

Isolation or Quarantine?

Isolation is used to separate ill persons who have

a contagious disease from others. It is often carried

out in a healthcare setting.

Quarantine is used to separate and restrict the

movement of well persons who may have been

exposed to a contagious disease to see if they

become ill. It is often carried out at home.

Death Rates

EVD is known and widely feared for being exceptionally deadly. The case fatality rate (CFR), the

percentage of infected individuals who do not survive, generally exceeds 50%, an extraordinarily

high rate among infectious diseases. The true CFR is an inherent property of the infectious agent

(in this case, the Ebola Zaire virus). However, the measured CFR is affected by the availability of

vaccines and specific treatments, as well as general medical care, among other factors. Perhaps

the most significant factor is how cases are counted; whether counts are limited, for example, to

cases in which EVD is confirmed with a laboratory test, or to hospitalized patients, or to patients

for whom an outcome (lived or died) is confirmed. Different approaches to case counting can

affect the measured CFR considerably.

WHO analyzed CFRs for the current outbreak in West Africa, limiting its analysis to patients with

confirmed outcomes. It found rates of about 70% in each of the severely affected countries—

Guinea (70.7%), Liberia (72.3%), and Sierra Leone (69.0%). In all three countries, hospitalized

patients in this group had somewhat lower CFRs (ranging from 61% to 67%) than patients who

were not hospitalized.6 Regardless of variations in measured rates, EVD is clearly a deadly

disease.

5

See for example Lauran Neergard and Paul J. Weber, “U.S. Hospital Sent Ebola-infected Patient Home,” Associated

Press, October 2, 2014, discussing initial failure of providers in a Dallas hospital to diagnose EVD in a patient.

6

WHO Ebola Response Team, “Ebola Virus Disease in West Africa—The First 9 Months of the Epidemic and

Forward Projections,” NEJM, September 23, 2014, Table 2, p. 11, http://www.nejm.org.

Congressional Research Service

2

Ebola: Basics About the Disease

Preventing Transmission

Prevention of human-to-human transmission of Ebola virus requires avoiding contact with body

fluids of those who are sick. As a result, EVD is not likely to be easily transmitted in community

settings in the United States. However, caregivers, including family members and healthcare

workers, face considerable risk of transmission. Barrier protections (called personal protective

equipment or PPE), liberal disinfection of premises and facilities housing EVD patients, and

careful handling of human remains and contaminated objects are essential.7 In resourceconstrained environments (such as in developing countries), consistent adherence to these

practices can be hampered by shortages of personnel and supplies, and other factors. However,

according to CDC, “virtually any hospital in the [United States] can do isolation for Ebola.”8

Therapies and Vaccines

No specific therapy or vaccine against EVD is approved by the U.S. Food and Drug

Administration (FDA) for use in the United States, or is available elsewhere in the world.

However, for more than a decade the U.S. government has funded research and development of

specific therapies (such as antiviral drugs) and vaccines against EVD for military force protection

and domestic biodefense purposes. Given the current outbreak, pharmaceutical companies, FDA,

and other federal agencies have accelerated their work on some promising products.9 Some

products are or may soon be available for investigational use (i.e., in clinical trials) both

domestically and abroad.

WHO assumes that EVD-specific therapies and vaccines will not be available in sufficient time or

amount to quell the current outbreak. It urges continued aggressive efforts to stop ongoing

transmission through contact tracing (i.e., identifying and monitoring all individuals who may

have been exposed to an infected patient) and use of protective measures.10

Non-EVD-specific treatments include fluids (orally or intravenously) to maintain hydration, and

blood transfusions to counter blood loss from hemorrhagic symptoms. Transfusions of blood,

serum, or plasma from EVD survivors have been given to some victims in order to provide

antibodies from the survivors. The effectiveness of this approach has not been demonstrated.11

Testing unproven therapies in the midst of an outbreak raises technical and ethical concerns. A

WHO committee has said that the use of investigational products is warranted for the current

outbreak.12 Experts disagree about the particulars of such use, however. For example, some say

7

See for example CDC, “Ebola Virus Disease: Prevention,” http://www.cdc.gov/vhf/ebola/prevention/index.html.

Comments of CDC Director Tom Frieden, “CDC Confirms First Ebola Case Diagnosed in the United States,” Press

Briefing Transcript, September 30, 2014, http://www.cdc.gov/media/archives.htm.

9

FDA, “2014 Ebola Outbreak in West Africa,” http://www.fda.gov/EmergencyPreparedness/Counterterrorism/

MedicalCountermeasures/ucm410308.htm; and CRS, Availability of Treatments for the Ebola Virus Outbreak in West

Africa, memorandum for general distribution, September 12, 2014, by (name redacted), 7-...., (name redacted), 7-....,

and (name redacted), 7-..... Contact authors for a copy.

10

WHO, Ebola Response Roadmap, August 28, 2014, Geneva, Switzerland, http://www.who.int/csr/disease/ebola/

ebola-response-roadmap/en/.

11

WHO, “Experimental Therapies: Growing Interest in the Use of Whole Blood or Plasma from Recovered Ebola

Patients (Convalescent Therapies),” September 26, 2014, http://who.int/mediacentre/news/ebola/26-september-2014/

en/.

12

WHO, “Ethical Considerations for Use of Unregistered Interventions for Ebola Virus Disease: Report of an Advisory

(continued...)

8

Congressional Research Service

3

Ebola: Basics About the Disease

that in order to understand whether an investigational product is effective, it must be studied by

comparing outcomes of groups of people who receive the product, and groups who receive a nontherapeutic drug or vaccine (i.e., a placebo) instead. Others feel that placebo comparisons are not

necessary, arguing that if a given investigational product were effective, it would be evident in

how it lowered the normally high case fatality rate of EVD, and more people would be able to

benefit from it.13 This issue often arises when clinical trials are carried out in developing

countries; the path(s) chosen in deploying investigational products for EVD in West Africa will

be examined in order to inform the response to outbreaks of EVD and other diseases in the future.

Outbreak Models and Projections

Guinea, Liberia, and Sierra Leone, countries without prior experience with EVD, have been

severely affected by the current outbreak. In late summer case counts in the three countries rose

precipitously. On September 22, WHO warned that “[u]nless Ebola control measures in west

Africa are enhanced quickly, ... numbers will continue to climb exponentially, and more than

[20,000] people will have been infected by early November.... ”14

The same week, CDC authors published outbreak projections for Liberia and Sierra Leone. The

model found that without further interventions to slow the outbreak (a worst case scenario), the

case count in the two countries could reach 1.4 million by January 20, 2015. Conversely, if 70%

of EVD patients were effectively isolated going forward, the outbreak in both countries would be

almost controlled by that same date.15

In light of concerns raised by the introduction of EVD into the United States, the CDC Director

has said that these concerns can best be alleviated by controlling the outbreak in West Africa.16

Additional CRS Products

•

CRS Report R43736, Ebola Virus Disease (Ebola or EVD): Experts List

•

CRS Report R43697, The 2014 Ebola Outbreak: International and U.S.

Responses, by (name redacted)

•

CRS Report IN10152, Increased Department of Defense Role in U.S. Ebola

Response, by (name redacted)

•

CRS Report IN10126, Safe at Home? Letting Ebola-Stricken Americans Return,

by (name redacted)

(...continued)

Panel to WHO,” August 17, 2014, http://www.who.int/csr/resources/publications/ebola/ethical-considerations/en/.

13

See for example Kai Kupferschmidt, “Ebola Vaccine Tests Needlessly Delayed, Researchers Claim,” Science

magazine, September 29, 2014, http://news.sciencemag.org/category/africa.

14

WHO, “Study Warns Swift Action Needed to Curb Exponential Climb in Ebola Outbreak,” press release, September

22, 2014, referring to the NEJM article at footnote 6, http://who.int/mediacentre/news/releases/2014/ebola-study/en/.

15

Martin I. Meltzer et al., “Estimating the Future Number of Cases in the Ebola Epidemic—Liberia and Sierra Leone,

2014–2015,” MMWR, vol. 63, Supplement, no. 3 (September 26, 2014), pp. 1-14, http://www.cdc.gov/mmwr/.

16

See for example comments of CDC Director Tom Frieden, “ CDC Confirms First Ebola Case Diagnosed in the

United States,” Press Briefing Transcript, September 30, 2014, http://www.cdc.gov/media/archives.htm.

Congressional Research Service

4

Ebola: Basics About the Disease

•

CRS Report R40570, Immigration Policies and Issues on Health-Related

Grounds for Exclusion, by (name redacted)

Author Contact Information

(name redacted)

Specialist in Public Health and Epidemiology

[redacted]@crs.loc.gov, 7-....

Congressional Research Service

5

EveryCRSReport.com

The Congressional Research Service (CRS) is a federal legislative branch agency, housed inside the

Library of Congress, charged with providing the United States Congress non-partisan advice on

issues that may come before Congress.

EveryCRSReport.com republishes CRS reports that are available to all Congressional staff. The

reports are not classified, and Members of Congress routinely make individual reports available to

the public.

Prior to our republication, we redacted names, phone numbers and email addresses of analysts

who produced the reports. We also added this page to the report. We have not intentionally made

any other changes to any report published on EveryCRSReport.com.

CRS reports, as a work of the United States government, are not subject to copyright protection in

the United States. Any CRS report may be reproduced and distributed in its entirety without

permission from CRS. However, as a CRS report may include copyrighted images or material from a

third party, you may need to obtain permission of the copyright holder if you wish to copy or

otherwise use copyrighted material.

Information in a CRS report should not be relied upon for purposes other than public

understanding of information that has been provided by CRS to members of Congress in

connection with CRS' institutional role.

EveryCRSReport.com is not a government website and is not affiliated with CRS. We do not claim

copyright on any CRS report we have republished.